Pfützner Science & Health - Personalized Treatment

The goal of this personalized treatment approach is not only to avoid elevated blood glucose, but also to stop disease progression, to protect the vasculature and potentially even reduce the degree of an existing atherosclerosis.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player


Type 2 Diabetes Is a complex disease with underlying disorders that progressively deteriorate over time if not adequately treated (ß-Cell dysfunction, Insulin resistance, increased hormonal activity of the visceral lipid tissue, chronic systemic inflammation).

In the course of disease progression, the secretion product of the pancreas is not able to control blood glucose levels and in consequence the glucose concentrations rise. In patients with type 1 diabetes, the immune system has destroyed the insulin-producing cells with the same final consequence.

The additional determination of specific „cardiodiabetes“ markers (intact proinsulin, adiponectin, hsCRP) helps to understand the severity of the underlying disorders and allows for determination of the individual diabetes phenotype.

Based on the individual phenotype, an individually tailored treatment can be defined. In case of a sufficient remaining ß-cell function, an attempt can be undertaken to“ re-boot“ the metabolism by a so called De-Escalation Treatment (DET).

In many cases, DET has helped to stop disease progression and sometimes has even allowed the metabolism to return to normal, or at least to delay the onset or progression of secondary disease complications.

Pfützner Science & Health “Beyond Glucose Control“-approach
Measurement of circulating functional proteins
  1. to understand and document the degree of severity of the underlying deteriorations leading to diabetes, by specific ELISA tests (Tecomedical and Immundiagnostik) and to determine the individual risk for atherosclerosis by macro-array tests for genotyping (Pharmgenomics).
  1. to accurately measure the individual vascular risk (not only just a theoretical risk percentage).
  1. to identify a treatment that results in normalization of the cardiodiabetes biomarkers and that is accompanied by normalization of glucose and HbA1c and a reduction in chronic systemic inflammation.
  1. to perform a De-Escalation Therapy (DET, if applicable) using a temporary multiple drug treatment to reduce ß-cell stress and to allowing the pancreas to recover and to re-built new insulin-producing ß-cells cells from stem.
Treatment targets:

Relieving, rebuilding and protecting ß-cell function   

Reduction of hormonal visceral lipid tissue activity.

Treatment of metabolic and vascular insulin resistance.       

Treatment of glucose toxicity